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e-mail address: drdivyabalu@gmail.com (D. Balakrishnan).Aditya Sudhalkar; Divya Balakrishnan ⇑; Subhadra Jalali; Raja NarayananAbstractPurpose: To determine the role of systemic steroids in improving visual acuity, preventing recurrence and hastening pigment
epithelial detachment resolution in IPCV patients.
Methods: Retrospective computer assisted comparative case series of consecutive patients with documented IPCV who did and
did not receive systemic steroids as part of their treatment regimen between 2007 and 2012. Patients who had systemic con-
traindication to steroid therapy were excluded from the steroid arm. Data collected included demographics, the best corrected
visual acuity, details of the ocular and systemic exam, the treatment offered, the follow-up period and the final visual and anatomic
outcomes. Outcome measures included the final BCVA, the time to resolution of the associated pigment epithelial detachment
(PED, if present), the recurrence rate and the associated side effects, if any. Appropriate statistical analysis was done.
Statistical significance: p < 0.05.
Results: 14 patients (14 eyes) had received systemic steroids in the stated period; these were comparedwith 26 consecutive patients
(26 eyes)whodid not.Meanage: 59.24 vs 62.38 years (A vsB).MeanbaselineBCVA: 1.86 ± 1.24 logMARvs 2.12 ± 1.48 logMAR (A vs
B). 8 females in Group A and 14 in Group B. 11 patients in group A and 19 in group B had associated systemic hypertension. Therapy
consisted of laser photocoagulation, anti-vascular endothelial growth factor therapy, photodynamic therapy or a combination of
these. Mean follow-up: 43.21 ± 11.32 months (Group A) vs 48.24 ± 9.75 months (Group B). BCVA at three months was significantly
better (0.84 ± 0.74 logMAR vs 1.16 ± 0.89 (p = 0.039). Final BCVA: 0.86 ± 0.78 logMAR (Group A) vs 1.29 ± 0.92 (Group B,
p = 0.042). 7 patients in group A and 12 in Group B had a recurrence (insignificant difference). 1 patient in Group A and 7 in
Group B had unresolved disease (persistent PED) at the end of follow-up (OR: 4.60; 95% CI 1.7–11.10).
Conclusion: Steroids appear to improve visual acuity and accelerate the resolution of the PEDs in patients with IPCV and large
PEDs, but do not seem to influence recurrence.
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Idiopathic Polypoidal Choroidal Vasculopathy (IPCV) is
considered to be a variant of neo-vascular Age Related
Macular Degeneration (AMD).1–4 The disease is characterized
by polypoidal dilatations of the choroidal vasculature in the
foveal or extrafoveal region, which results in hemorrhagic orexudative pigment epithelial detachments. In the natural his-
tory of PCV, half of the patients had persistent leakage or
repeated bleeding and a poor visual outcome.4 Sho et al. also
reported severe visual loss in 35% of eyes5 with IPCV.
There is a lack of evidence regarding the most appropriate
therapy or a combination thereof for treatment of polyps.6–11
The role of anti-VEGF monotherapy in IPCV is unclear, ande:
al.com
Steroids in polypoidal vasculopathy 15studies show that photodynamic therapy is more effective in
terms of aiding IPCV closure,6,10,11 whereas anti-VEGF ther-
apy acts mainly to reduce macular edema and improve vision.
The EVEREST trial showed that photodynamic therapy, alone
or combined with anti-VEGF therapy was better than anti-
VEGF monotherapy alone.6 Argon laser photocoagulation
has also been attempted successfully in effecting the closure
of polyps.7 Combination therapy often yields favorable
results.
Thus, while treatment of these lesions is desirable, there is
no clear consensus regarding the optimal management strat-
egy. Also, patients with IPCV tend to have large serous or
hemorrhagic pigment epithelial detachments (PEDs) which
may rupture leading to break through vitreous hemorrhage
and RPE rips and can severely affect vision.1–4,12
Inflammation is said to play a role in the pathogenesis of
wet AMD (although it is still considered inconclusive).13–16
There is a report of the use of local steroids as an adjunct
to treatment for IPCV.17,18 The role of oral steroids in IPCV,
however, is unclear and, to an extent controversial, men-
tioned in an earlier publication from our institute,12 wherein
a patient with a large, tense pigment epithelial detachment
was treated with steroids prior to further treatment. The
underlying basis is of course that IPCV is possibly an inflam-
matory process and may respond to steroids.
This study was undertaken with the aim of determining the
role of oral steroids in IPCV, specifically whether it alters
visual recovery, IPCV recurrence and PED resolution.
Complications, if any, were to be noted as well.Methods
A retrospective data search was made for all patients
diagnosed to have IPCV between January 2007 and 2012.
The data collected included demographics, details of the
ocular exam, the special investigations performed (such as
fluorescein and indocyanine green angiography, and ocular
coherence tomography scans), the treatment given and
whether steroids were used. The baseline and final corrected
distance visual acuity were measured using a logMAR chart
and noted. Patients of IPCV who presented with break-
through hemorrhage were excluded from the analysis. The
review adhered to previously set guidelines for retrospective
reviews.19 The institutional review board for LV Prasad Eye
Institute, Hyderabad, approved the study. The study adhered
to the tenets of Helsinki. Patient consent for possible aca-
demic use of data had been obtained at the time of the first
visit.
All patients received one or a combination of the following
treatment modalities: anti-VEGF injections, frequency dou-
bled Nd:Yag laser photocoagulation to polyps that were
extrafoveal and photodynamic therapy to polyps that were
<200 lm away from the foveal center. Photodynamic therapy
was also offered to patients who did not respond to the
aforementioned modalities.
Patients with large, tense hemorrhagic or serous pigment
epithelial detachments near the polyp (as identified on indo-
cyanine green angiography) at risk for a retinal pigment
epithelium rip (RPE rip) were given oral steroids (after a physi-
cian consult) for a fortnight at 0.5 mg/kg body weight fol-
lowed by a weekly taper of 10 mg prior to any ocular
intervention (such as laser photocoagulation or intravitrealinjections). Administration of oral steroids was with informed
consent from the patient. If the lesion identified on angiogra-
phy was away from the fovea and the pigment epithelial
detachment, laser photocoagulation was performed first, fol-
lowed a week later by intravitreal ranibizumab. If the lesion
showed no signs of reduction on serial ocular coherence
tomography (i.e. less than 10 lm reduction in size of PED
observed on serial OCT scans for two consecutive months),
the patient was either started on oral steroids (0.5 mg/kg
body weight) or observed (investigator discretion; subse-
quently described as Group A and Group B). If the polyp
was identified to be less than 200 lm from the foveal center,
photodynamic therapy was offered, with or without anti-
VEGF agents (as decided by the treating physician). Care
was taken to include the fine vascular network in the treat-
ment diameter during photodynamic therapy.
Patients were followed up monthly for 6 months after
treatment, and then 3 monthly thereafter. Indocyanine
angiography was repeated at months 3, 6, 9 and 12 after
completion of therapy and then as needed. OCT raster and
macular cube scans were repeated at each follow-up. The
change in PED dimensions, the subretinal fluid and retinal
thickening was monitored on serial OCT scans.
The patients were divided into two groups: Those that
received oral steroids as an adjunct to oral therapy (Group
A) and those that did not (Group B).
Descriptive statistics were used to analyze the results. The
paired t-test was used to analyze the change in visual acuity
with treatment within both groups. The odds ratio was used
to analyze whether there was a difference in resolution of the
PED and/or the disease process between the two groups.
The number of patients who came back with a recurrence
in each group was noted. Complications, both ocular and sys-
temic, if any, were noted for both groups. The time to reso-
lution of PED was compared using the unpaired t-test.
Statistical significance was set at p < 0.05.
The primary outcome measure was the proportion of
patients with resolved PEDs at the end of the follow-up per-
iod in each group. Secondary outcome measures were the (1)
corrected visual acuity at three months after completion of
therapy and at final follow-up in both groups, (2) the recur-
rence rate in both groups and (3) the complications noted
in both groups.Results
A total of 14 patients (Group A) had received steroids as
an adjunct to therapy for IPCV in the said period. These
patients were compared to 26 consecutive patients of IPCV
undergoing treatment in the same period who did not
receive oral steroids (Group B).
9 patients in Group A and 14 in Group B had received
laser photocoagulation to the polyp followed one week later
with intravitreal anti-VEGF injections, which were repeated as
required, depending on the response. The remaining
patients received photodynamic therapy for subfoveal or jux-
tafoveal polyps (as described earlier). The mean number of
injections in Group A was 2.85 ± 1.23 vs 2.60 ± 1.32 in
Group B. All patients in Group A and 23 patients in Group
B had associated large PEDs. The median PED height as mea-
sured on ocular coherence tomography scans was
412 ± 108 lm vs 429 ± 122 lm in Groups A vs B respectively.
Figure 1. Serial fundus photographs of a patient from Group 1 prior to any treatment (a) and two months after laser photocoagulation and intravitreal
anti-VEGF injection to the leakage site as identified on indocyanine green angiography (b). As seen, there was little change in the PED after local therapy.
At final follow-up (c), i.e. three months after laser photocoagulation and one month after initiation of oral steroids, the PED had resolved substantially.
The picture remained unchanged at final follow-up or one year after laser therapy.
Figure 2. The exact site of laser photocoagulation using frequency doubled Nd:Yag laser (a) for the same patient. The parameters used are as
mentioned. Figure (b) depicts the ICGA picture prior to laser therapy and Figure (c) at final follow-up.
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Group B. The median age of the patients in Group A was
59.24 (52–73) years vs 62.38 (53–70) years in Group B
(p = 0.31). 9 patients in Group A and 12 in Group B were
pseudophakic. 11 patients in Group A and 19 in Group B
had associated systemic hypertension, and a total of 4
patients in each group had type II diabetes mellitus, without
evidence of diabetic retinopathy. The median follow-up was
43.21 ± 11.32 months (Group A) vs 48.24 ± 9.75 months
(Group B). 1 patient in Group A had persistent PED at the
end of the follow-up period vs 7 in Group B. The median
baseline visual acuity was 1.86 ± 1.24 logMAR vs
2.12 ± 1.48 logMAR (A vs B). The median visual acuity at
three months after treatment completion was
0.84 ± 0.74 logMAR (Group A) vs 1.16 ± 0.89 (Group B;
p = 0.039). The visual acuity was thus significantly better in
both groups as compared to baseline (Group A: 0.033;
Group B: 0.047). The median final visual acuity was
0.82 ± 0.78 logMAR (Group A) vs 1.19 ± 0.92 (Group B, A
vs B: p = 0.042). Group A showed better visual acuity.There was also significant improvement in the visual acuity in
both groups (Group A: 0.03, Group B: 0.043). The odds that
a patient from Group B would have persistent PEDs at the
end of the follow-up period were 4.60 (95% CI 1.7–11.10). 4
patients in Group B and none in Group A had breakthrough
bleeds during the course of treatment; 3 of these had submac-
ular hemorrhage and one had vitreous hemorrhage. These
occured a median of 3.56 ± 1.24 months after completion of
therapy. The median time to resolution of the PED was
2.64 ± 1.25 months in Group A vs 8.15 ± 2.42 months in
Group B (p = 0.012, significant difference).
7 patients in Group A and 12 in Group B had a recurrence.
The difference was statistically insignificant (p = 0.28). All
were offered photodynamic therapy as a second line of treat-
ment except 1 patient in Group B who was advised repeat
laser photocoagulation.
None of the patients in either group had treatment related
adverse reactions. None of the patients in Group A had any
systemic side effects secondary to steroids and no patient
required discontinuation of therapy because of steroids.
Figure 3. Serial OCT scans of the same patient. (a) was at presentation; two months after laser photocoagulation, there was little change in PED size and
there was subretinal fluid noted (b). One month after initiation of oral steroids, there was complete resolution of both the PED and SRF.
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A tailored approach to each patient with IPCV is recom-
mended. This study shows good results in terms of PED res-
olution in patients who have otherwise received local therapy
appropriate to the clinical and angiographic picture.A troublesome complication of large tense serous or hem-
orrhagic PEDs is pigment epithelial rip and/or breakthrough
hemorrhage, be it suprachoroidal, subretinal or vitreal.
Additionally, local therapy in the form of laser photocoagula-
tion or intravitreal injections may actually initiate RPE rip or
breakthrough hemorrhage, especially in patients with large
18 A. Sudhalkar et al.PEDs.20,21 A predictive factor for such an event is determined
by the size of the PED, and a positive correlation has been
noted between PED size and the occurrence of a RPE
rip.22–25
The role of inflammation in the pathogenesis of AMD in
general and IPCV in particular has been, to an extent, ana-
lyzed. Authors have used triamcinolone injections, intravitre-
ally18 or subtenon,17 as a combination therapy with PDT in
AMD. Authors have found that non-PCV lesions do show
some benefit with local steroid injection with respect to
reduced recurrence rates. An earlier publication from our
institute describes a patient of IPCV who responded to oral
steroids with respect to reduction in PED size.12
This study shows greater visual benefit in patients of PCV
who received steroids as an adjunct to local therapy, contrary
to other studies; it should, however, be borne in mind that
our analysis was retrospective. We too did not notice any sig-
nificant difference with respect to recurrence in both groups.
But oral steroids appeared to help accelerate the fluid/hem-
orrhage reabsorption process. We speculate that this proba-
bly is a consequence of reducing inflammation and
subsequent leakage. As has been shown in an earlier publica-
tion, subretinal fluid resolution precedes PED reduction,26
and PED reduction may be influenced by PCV persistence
and/or recurrence. A persistent, tense PED can give rise to
breakthrough hemorrhage or even RPE rips, with or without
treatment. We propose that steroids probably help reduce
the chances of such an occurrence by hastening its resolution.
Additionally, steroids may help quell increased inflammation
secondary to therapy such as laser photocoagulation or pho-
todynamic therapy, as is seen in Figs. 1–3. Thus steroids
probably help accelerate the resolution process that has
been initiated by laser photocoagulation or photodynamic
therapy and prevent an inflammatory increase in fluid.
The use of oral steroids did not seem to influence recur-
rence in our study.
A look at available literature suggests that combination
therapy is superior to anti-VEGF monotherapy for manage-
ment of polypoidal vasculopathy. The EVEREST study6
looked at the role of combination therapy with verteporfin
based photodynamic treatment with or without intravitreal
ranibizumab vs monotherapy with intravitreal ranibizumab.
The authors concluded that PDT, either alone or in combina-
tion with intravitreal ranibizumab was superior to ranibizu-
mab monotherapy in achieving complete polyp regression.
Additionally, aflibercept has been shown to be beneficial in
patients with refractory polypoidal vasculopathy who demon-
strate tachyphylaxis to ranibizumab,27 as well as in patients
with treatment naïve PCV.28 The authors suggest that afliber-
cept may halt exudation and thus expedite PED resolution.28
This article has the usual limitations of a retrospective
study. Additionally, there was no standardized treatment
protocol in terms of the exact PED size beyond which ster-
oids would be advisable. Also, there may be hesitation in pre-
scribing oral steroids to patients in the age bracket
described, given that steroids carry with them well known
adverse effects. Despite these limitations, however, this
study presents certain features of interest: This study is the
largest in terms of patients who received anti-inflammatory
therapy to supplement local treatment in patients with
IPCV. In addition to recurrence rates and visual benefit, we
also look at PED resolution between the two arms, as tensePEDs are likely to give way and create further problems.
Steroids appeared to aid as well as hasten the PED resolution
as per our findings. The role of steroids in PCV is thus not
clear, and future prospective trials are warranted.
To conclude, oral steroids appear to improve visual out-
comes and aid PED resolution in patients with IPCV when
prescribed as an adjunct to treatment. A randomized trial will
help ascertain conclusively the role of steroids as an aid to
IPCV management.Conflict of interest
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